Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Rivian Automotive, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Rivian Automotive, Inc. trades at $16.45 (market cap $22.44B). The key difference: Rivian Automotive, Inc. is far larger — about 5× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | RIVN | |
|---|---|---|
Market Cap | $4.49B | $22.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $22.45 |
52-Week Low | $20.06 | $11.64 |
Enterprise Value | $3.69B | $24.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Rivian (RIVN) trades at $16.49, down 11.49% amid a 75 million share offering announced July 7, 2026, raising dilution concerns despite recent quarterly EPS beats. The stock shows a bullish technical signal with moving averages supporting upside, but RSI indicates overbought conditions. Revenue grew to $5.39B in 2025, yet net losses persist at -$3.65B, with cash flow negative but improving. Analyst consensus is mixed with a $21.29 price target.
Outlook remains challenged by high cash burn and dilution risks, but cost reductions and DOE loan potential offer long-term growth avenues. Investors face volatility from EV competition and execution hurdles, though institutional buy ratings suggest cautious optimism for profitability milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
